INTRODUCTION

Prostate cancer (PCa) is the second most common malignancy among men globally, second only to lung cancer.[1] Forecasts for 2023 predict approximately 288,300 new PCa cases in the United States, accounting for 29% of all male cancer diagnoses and resulting in approximately 34,700 deaths, or 11% of all male cancer-related deaths,[2] posing a significant health and economic burden on men. Clinical staging through the tumor-node-metastasis system and pathological grading using the Gleason score have long served as the foundation for assessing PCa prognosis and guiding treatment.[3,4] Treatment options for localized PCa include active surveillance, radical surgery, or radiation therapy; however, up to 30% of patients still experience recurrence and metastasis following these treatments.[5] For advanced and metastatic PCa, androgen deprivation therapy (ADT), aimed at inhibiting androgen receptor (AR) signaling, is the primary strategy. Nevertheless, most patients who undergo ADT progress to a castration-resistant phase, termed castration-resistant PCa (CRPC), for which effective treatments are currently lacking.[6,7] Thus, early and precise assessment and management of the tumor are imperative.

A major challenge in the clinical management of PCa is insufficient early characterization of the tumor. Current diagnostic practices primarily rely on cytopathological examination, namely, microscopic analysis of prostate tissue biopsy samples, to characterize tumors. This allows for the direct identification of cancer cells and their morphological traits, whereas the Gleason grading system assesses tumor differentiation,[8] offering vital insights into disease status and prognosis. However, with the advancement of tumor molecular research, the critical role of the genetic heterogeneity of PCa in its development and progression has become increasingly acknowledged. The genetic heterogeneity of PCa signifies that even in the early stages, morphological patterns can vary significantly among different patients. Within a single tumor, cells displaying similar morphological characteristics can possess extensive variations in gene expression and mutations, influencing the tumor’s growth rate, aggressiveness, and treatment response.[9]

While cytopathological examination provides essential background information on cell morphology, it relies on molecular diagnostic methods to capture genetic heterogeneity and more precisely characterize cancer. In the future, an important trend in PCa management will be the integration of cytopathology with molecular diagnostics through a multimodal diagnostic approach. Cytology continues to play a crucial role in determining the morphological features of tumors and provides suitable cellular material for genetic and molecular analysis, while molecular diagnostics offer in-depth molecular details, such as specific gene mutations,[9] gene fusions,[10] epigenetic changes,[11] and non-coding RNAs.[12] By detecting these variations, they uncover the molecular mechanisms of cancer and identify potential therapeutic targets, offering crucial information for early diagnosis, prognosis assessment, and treatment decision-making in PCa.

This review summarizes the latest research advancements in molecular diagnostics for PCa, focusing on cutting-edge molecular biomarkers and associated detection technologies, and reaffirms the indispensable value of cytology in supporting the interpretation of molecular diagnostic findings and obtaining high-quality samples for molecular diagnostics.

GENETIC BIOMARKERS TMPRSS2-ERG fusion

TMPRSS2, a gene responsive to androgens, produces a serine protease unique to the prostate, exhibiting specificity to prostate tissue.[13] Its operational significance hinges on the gene’s fusion with E-twenty six (ETS) transcription factors, such as ETS-Related Gene (ERG), which is a transcription factor with oncogenic potential.[14-16] The TMPRSS2:ERG gene fusion represents the most common genetic modification in PCa, occurring in about half of all PCa cases.[14-16] This particular fusion leads to the increased expression of ERG, contributing to the observed upsurge in cell proliferation, angiogenesis, and invasion of PCa cells.[17]

In recent years, the TMPRSS2:ERG fusion has been identified as an emerging biomarker for PCa, offering new avenues for diagnosis and understanding the disease’s pathology.[10,18] According to Mosquera et al.,[19] TMPRSS2-ERG fusion transcripts occur within prostatic intraepithelial neoplasia, and their expression levels correlate with the malignancy of PCa, improving the positive predictive value of finding TMPRSS2-ERG fusion PCa in subsequent biopsies, marking a significant advance in identifying precancerous lesions of PCa.

At the same time, many studies have emphasized the value of detecting TMPRSS2-ERG fusion in urine samples. Molecular genetic analysis of exfoliated prostate epithelial cells in urine samples to detect the levels of TMPRSS2:ERG fusion transcripts, it may offer advantages over serum prostate specific antigen (PSA) in some aspects of PCa diagnosis.[20] For example, a test developed by Mlabs of the University of Michigan for urine samples post-digital rectal examination (DRE), termed the Mi-Prostate Score, revealed that the sensitivity of TMPRSS2-ERG ranges from 24.3% to 37%, and its specificity reaches 93%.[21] Traditional PSA tests have a specificity ranging from 20% to 40%, thus, the heightened specificity of the TMPRSS2:ERG fusion acts as an effective adjunct to PSA. Notably, Rice et al.[22] analyzed ERG mRNA in the urine of 237 men and demonstrated the 80% predictive accuracy of the TMPRSS2:ERG fusion in diagnosing PCa in men with PSA levels ≤4.0 ng/mL.

Recent research has highlighted the combined diagnostic significance of TMPRSS2:ERG and prostate cancer antigen 3 (PCA3) in urine samples. The findings indicate that integrating urinary PCA3 and TMPRSS2-ERG levels with serum PSA substantially improve the detection of aggressive PCa (characterized by a Gleason score ≥ 7) at the time of the initial biopsy. Moreover, this combined diagnostic approach has been shown to decrease the number of unnecessary biopsies by 42%.[23-25]

PTEN loss

The PTEN gene, known for its tumor-suppressing functions, facilitates cell apoptosis by inhibiting activation of the phosphoinositide 3-kinase/protein kinase B(PI3K/AKT) signaling pathway, which is crucial for maintaining regular cell growth and preventing tumor development.[26,27] Studies have shown that alterations in the PTEN gene, including copy number variations, structural rearrangements, and point mutations, lead to its deactivation. These changes are present in approximately 20% of primary PCa specimens and in 50% of CRPC cases, culminating in a loss of its tumor-suppressive abilities.[28,29]

Extensive research has demonstrated a strong correlation between the frequency of PTEN inactivation and more aggressive PCa features, worse prognosis, and diminished responsiveness to conventional endocrine therapy.[30-32] Significantly, liquid biopsy analysis based on the PTEN genomic status has been applied clinically as a rapid, noninvasive strategy to provide information for treatment decisions. In a clinical trial exploring the combination of abiraterone with PI3K/AKT inhibitors in CRPC patients, researchers used blood-based circulating tumor cells (CTCs) PTEN fluorescence in situ hybridization testing and found that PTEN-deficient CRPC patients had significantly reduced survival rates and markedly affected responses to current therapies.[33,34]

Moreover, in localized PCa, the status of the PTEN gene has been recognized as a critical predictive marker for the progression of the disease, aiding in the selection of intervention timing for patients under active surveillance. For example, through immunohistochemical examination of PTEN in biopsy samples, researchers found that PTEN loss in localized PCa is associated with an increased risk of non-organ-confined PCa, indicating that these patients may benefit more from radiation therapy or radical prostatectomy.[35,36]

MYC amplification

The MYC gene is intimately linked with numerous cancers and tumor-specific traits. In studies across 33 cancer types encompassing genomics and proteomics, MYC gene amplification was identified in 28% of tumor samples, underscoring its widespread impact.[37] As a distinct oncogenic driver, the MYC gene encodes a nuclear DNA-binding protein pivotal for cell cycle regulation. This gene and its outputs foster cell proliferation, immortalization, dedifferentiation, and transformation, thereby accelerating tumor initiation and progression.[38,39] These features highlight the potential of MYC as both a therapeutic target and a biomarker.

Reports indicate that amplification of the Myc gene is observed in 89% of PCa patients.[40] Amplification of the MYC gene is linked to increased Gleason scores, increased disease aggressiveness, and reduced survival in PCa patients, serving as a key driver of disease worsening and metastasis.[41-43] Research by Zhang et al.[44] has shown that overexpression of MYC disrupts the transcriptional program of the AR, which plays a pivotal role in PCa development. This indicates that elevated levels of MYC amplification could accelerate the progression of PCa to metastatic and castration-resistant phases. Local radiotherapy stands as an essential treatment for the early-stage PCa. Investigations have highlighted a link between variations in c-Myc copy number in PCa and genomic instability. Notably, PCa patients exhibiting high c-Myc expression who receive radiotherapy are at increased risk of disease recurrence and metastasis compared to those with lower c-Myc expression, indicating that radiotherapy might be less effective in these individuals.[45] Utilizing cytological methods such as liquid biopsy to monitor MYC amplification could aid in identifying patients who might benefit from alternative treatments or combination therapies, thereby improving personalized treatment plans and outcomes.

AR mutation and amplification

During the development of PCa to CRPC, the primary driver is aberrant activation of the AR signaling pathway. This involves mechanisms such as AR mutations,[46] amplification of the AR gene and its enhancers,[47] and the emergence of AR splice variants (AR-Vs),[48] rendering PCa sensitive to low androgen levels.[49]

Reports reveal that approximately 80% of CRPC patients exhibit AR overexpression, and 30–50% of their tissue samples exhibit AR gene amplification.[50] Moreover, nearly 60% of metastatic PCa patients have CTCs showing AR gene amplification and mutation.[51] Although the prognostic implications of AR amplification and mutations are not fully understood, they are recognized as negative prognostic indicators in the circulating cell-free DNA (cf-DNA) of metastatic CRPC (mCRPC) patients.[52-54]

At present, current attention is focused on AR gene structural rearrangements or alternative splicing that produce ARVs, such as the classic AR-V7.[55] A recent systematic review and meta-analysis conducted by Khan et al.[56] evaluated the clinical relevance of AR-V7 detection in liquid biopsy (primarily blood), showing that the presence of AR-V7 in such biopsies is an important clinical biomarker associated with overall survival (OS), progression-free survival (PFS), and PSA-PFS in CRPC patients receiving AR antagonist therapy. Detecting AR-V7 in liquid biopsy from CRPC patients has prognostic and predictive capabilities, a finding with high clinical relevance. At present, tests for analyzing AR-V7 status in blood CTCs have been commercialized and can be used in clinical practice, facilitating the assessment of AR-V7 status in patients with CRPC and highlighting the value of fluid biopsy in providing crucial prognostic and treatment-related information.[57]

EPIGENETIC BIOMARKERS DNA methylation

DNA methylation, the addition of methyl groups to DNA molecules, can result in the silencing of genes and decreased expression within promoter regions. This prevalent type of epigenetic alteration is linked to the development of multiple cancer types.[58-61] Considering the high incidence of abnormal DNA methylation in PCa-surpassing the frequency of genetic alterations-DNA methylation patterns have emerged as promising candidate biomarkers.[62,63]

In their research, Kim et al.[64] examined tissue samples from 53 patients who had undergone radical prostatectomy, comprising 42 cases of PCa and 11 cases of prostatic hyperplasia. Their findings demonstrated that the prognostic statistical significance of increased and decreased methylation area under the curve (AUC) values were 0.99 and 0.98, respectively, which were markedly higher than the 0.79 associated with PSA. This finding suggested that DNA methylation assessment could offer a more effective diagnostic method for PCa compared to the conventional PSA test.

The methylation of glutathione S-transferase P1 (GSTP1) is common in PCa, impacting about 90% of patients. It functions as an epigenetic biomarker for the early cancer detection.[65] The methylation-specific polymerase chain reaction (MSP) method can successfully detect GSTP1 methylation in CTCs and cf-DNA in blood samples. In addition, highly specific quantitative MSP methods can detect GSTP1 methylation in tissue biopsy samples to accurately differentiate between benign and malignant prostate lesions.[66] Based on this method, commercially available tests have been developed and are primarily used for clinical assessment of the necessity for repeat prostate biopsies.[67,68]

Identifying DNA methylation biomarkers through measurement aids in risk stratification among PCa patients. For example, the methylation status of specific genes, such as high methylation of actin-like 6B and low methylation of transcription elongation regulator 1, is associated with aggressive tumor traits and poor prognosis. These methylation patterns can serve as independent predictors of recurrence in localized PCa,[69] potentially guiding more aggressive treatment for individuals identified as high-risk due to these methylation patterns. Methylation analysis further serves as a diagnostic measure for uncommon variants of PCa. Berchuck et al.[70] constructed a predictive framework predicated on variations in methylation across different types of PCa. This model was utilized on a group of 48 patients, consisting of nine cases of neuroendocrine PCa and 39 cases of castration-resistant prostate adenocarcinoma, the analysis achieved a sensitivity of 100% and a specificity of 90% for identifying neuroendocrine cancer.

Histone modifications

Another epigenetic alteration observed in PCa involves histone modifications. Histones, proteins in eukaryotic organisms, facilitate DNA winding into nucleosomes. These modifications, such as acetylation, methylation, phosphorylation, ubiquitination, and SUMOylation, lead to changes in chromatin structure. Such changes regulate the processes of DNA transcription, replication, and repair, or they influence the cell cycle, consequently facilitating the development of cancer.[71-73]

Growing research underscores the crucial role that histone modifications play in the onset and advancement of PCa. The levels of known histone modification markers, such as H3K27me3,[74] H4R3me2,[75] H3K9ac,[76] and H4K20me1,[77] are closely associated with the malignancy of PCa. Furthermore, these markers have been shown to effectively predict the risk of PCa recurrence, underscoring their significance in clinical prognosis.

While DNA methylation analysis is a well-established method, the analysis of histone modifications offers significant variability and adaptability, although direct examination of these modifications presents substantial challenges due to their complexity and cost. Current clinical research on histone modifications as biomarkers for PCa primarily focuses on the enzymes responsible for these modifications. For instance, the histone methyltransferase family, which is vital for gene transcription regulation, catalyzes methylation at specific gene markers in promoter regions, influencing gene expression.[78] KMT1B is upregulated in PCa cells, enhancing androgen-dependent activity through interaction with the AR.[79,80] The lysine methyltransferase SET and MYND domain-containing protein 3 are upregulated in PCa and are associated with enhanced cell migration and proliferation.[81] The increased expression of the histone-lysine N-methyltransferase SETDB1 is associated with prognosis and is thought to contribute to PCa bone metastasis through the WNT signaling pathway.[82] Protein arginine methyltransferase family members, including protein arginine N-methyltransferase 5 that catalyzes the methylation of histone arginine at H4R3, are abnormally expressed in PCa cells. This leads to the epigenetic silencing of several tumor suppressor factors, thereby facilitating the growth of PCa cells.[83] Histone acetyltransferases primarily participate in the acetylation of histones, and their increased activity can promote PCa through the acetylation of histones or transcription factors, for example, p300 and CREB-binding protein enhance the transcriptional activity of AR by acetylating it, which is a poor prognostic marker for the progression of PCa to CRPC.[84,85] At present, the clinical application of these markers is limited, mainly due to the limitations of analytical technologies. Immunohistochemistry is the only method used clinically at present, but it offers a promising avenue for further development.

RNA methylation

In addition to DNA methylation and histone modifications, in recent years, researchers have discovered numerous base modifications in mRNAs and nc-RNAs, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), and N1-methyladenosine, these modifications are known as methylation of RNA.[86]

m6A is the most common form of mRNA methylation and significantly affects RNA stability and translation efficiency. In PCa, the aberrant regulation of m6A is closely associated with the onset, development, and metastasis of tumors. Research indicates that specific m6A modification patterns can serve as potential molecular markers for PCa, helping to identify different stages of the disease and predict patient prognosis.[87] Several studies have utilized RNA sequencing data from PCa tissue samples at various stages to establish m6A risk-related prognostic models for assessing the treatment outcomes and prognosis of metastatic PCa patients. These studies demonstrate that m6A scores are significantly correlated with prognostic indicators such as Gleason scores and metastatic risk, indicating the potential of m6A scoring as a molecular biomarker for evaluating prognosis through histopathological analyses.[88-90] Further, investigations reveal that the expression levels of m6A methylation regulators, including the methyltransferase-related proteins METTL3 and METTL14, are significantly positively associated with the malignancy of PCa. The strong correlation suggests that these methylation regulators may also serve as promising biomarkers for PCa, offering potential targets for diagnostic and therapeutic interventions.[91,92]

In addition, m5C is also a common RNA modification in PCa, and NSUN2, the sole m5C methyltransferase, has been proven to be an indicator of poor prognosis in PCa patients.[93] In conclusion, RNA methylation-related molecules have significant potential as diagnostic biomarkers for prognosis and disease monitoring in PCa patients. However, their detection technologies and clinical applications still require further exploration.

NC-RNA BIOMARKERS MicroRNAs

MicroRNAs (miRNAs) are a category of small, nc-RNA molecules, typically 17–25 nucleotides long, that regulate gene expression post-transcriptionally. An increasing number of studies have investigated the potential use of miRNAs as biomarkers for cancer diagnosis, prognosis, and treatment, including PCa, and have correlated their levels with clinicopathological parameters.[94-97] In addition, miRNAs can be repeatedly extracted from various biological samples, including biopsy tissues[98] or bodily fluids[99-100] (plasma, serum, and urine), and are generally stable and resistant to various storage conditions, making them attractive molecular biomarkers for PCa.

Current research on miRNAs as biomarkers for PCa mainly focuses on two aspects: single miRNA markers and multimiRNA diagnostic models. A significant drawback of the first approach is that the results from different studies may conflict or suffer from detection errors. At present, acknowledged single miRNA markers, such as miR-21,[101] miR-34a,[102] miR-107,[103] and miR-199a-3p,[104] are significantly correlated with PCa stage and adverse outcomes, and have been validated in CTCs testing.[105,106] However, unfortunately, the diagnostic efficacy of these methods does not seem to surpass that of PSA. Several studies have demonstrated the potentially superior performance of multi-miRNA diagnostic models. For example, Porzycki et al.[107] developed and validated a composite model based on miR-21, miR-141-3p, and miR-375, achieving a sensitivity of 93% and a specificity of 63% in predicting PCa from serum samples.

A study that analyzed miRNA expression differences in urine samples from diverse groups of patients developed and validated a urinary exosome 3-miRNA diagnostic ratio model, which includes miR-24-3p, miR-222-3p, and miR-30c-5p. This model is capable of predicting biopsy results for individuals in the PSA gray area (4–10 ng/mL) and for those with a negative DRE, offering an AUC that is superior to the AUC of PSA (AUC: 0.627 vs. 0.519), effectively screening patients who need prostate biopsies when PSA tests fail.[108] Furthermore, studies have indicated that a composite model comprising miR-151-3p, miR-141, and miR-16 offers promising diagnostic efficacy in detecting mCRPC.[109] However, these multimiRNA models might necessitate further validation within larger, independent cohorts to verify their diagnostic reliability and clinical applicability.

Long nc-RNAs

Research focusing on long ncRNAs (lncRNAs) as specific diagnostic markers for PCa is currently drawing significant attention. Among them, PCA3 stands out as the most thoroughly investigated and established lncRNA biomarker for PCa to date.

In 1999, Bussemakers et al.[110] first identified the overexpression of PCA3 in PCa. Further, research revealed that PCA3 is overexpressed in 95% of PCa cases and is nearly undetectable in normal prostate tissues and other malignant non-prostate tissues, indicating that it is a highly specific biomarker for PCa.[111,112]

In 2012, the PROGENSA assay, a diagnostic test for measuring PCA3 levels in urine, was approved by the United States Food and Drug Administration for the diagnosis of PCa.[25] Among biomarkers currently used in the clinic, urinary PCA3 levels may offer greater specificity and sensitivity than PSA and similar markers.[113,114] A recent meta-analysis that assessed PCA3 found that the sensitivity and specificity of the urinary PCA3 assay were 0.65 and 0.73, respectively.[115] However, PCA3 is primarily employed to circumvent repeat biopsies in men with negative results, as there is ongoing debate regarding the ability of PCA3 expression levels to evaluate the stage and aggressiveness of PCa.[116-118]

In addition, The PCa-associated transcript-1 (PCAT1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and small nucleolar RNA host gene 1 have been recognized as potential biomarkers for PCa.[119] PCAT1, which is highly specific to PCa, is overexpressed in most PCa tumors, particularly in advanced, metastatic tumors. Transcriptome analyses have identified PCAT1 as the highest-ranked and most significantly upregulated lncRNA in PCa tissues.[120,121]

MALAT1 is recognized as another potential diagnostic marker for PCa. Ren et al.[122] reported that high levels of MALAT1 expression in PCa tissues were strongly associated with elevated PSA levels, higher Gleason scores, advanced tumor stages, and resistance to castration therapy. In a study involving 434 patients by Ren et al.[123], the presence of MALAT1 in urine was found to surpass the levels of PSA and free PSA before biopsy, indicating that MALAT1 is an independent marker for predicting PCa. Moreover, in patients with PSA levels exceeding 4 ng/mL, mini-RNAs derived from MALAT1 could potentially serve as a promising plasma biomarker, enhancing the diagnostic precision for predicting the outcomes of prostate biopsies.

Circular RNAs (circRNAs)

Due to their circular structure, circRNAs are highly stable against degradation by RNA exonucleases, In addition to bodily tissue, circRNAs can also be detected in human bodily fluids such as blood and urine making them ideal candidates as molecular biomarkers for PCa.[124,125]

In PCa, several circRNAs have been studied, Li et al.[126] found that circ_0044516 is overexpressed in PCa, and further, cellular experiments showed that downregulation of circ_0044516 can inhibit the proliferation and metastasis of PCa cells. In addition, the expression levels of hsa_ circ_0001275 in plasma can reflect the trends in PSA levels at specific disease time points and may be associated with resistance to enzalutamide.[127] Zhong et al.[128] identified 160 autophagy-related circRNAs and constructed a circRNA signature consisting of five circRNAs: hsa_circ_0001747, hsa_circ_0002100, hsa_circ_0000280, hsa_circ_0000437, and hsa_circ_0001085. Univariate and multivariate Cox regression analyses showed that these circRNAs are independent prognostic indicator for PCa patients. Unfortunately, although research on circRNAs as diagnostic biomarkers for PCa has made preliminary progress, there are still some challenges in their clinical application, including the standardization of circRNA detection techniques, improvements in specificity and sensitivity, and validation in large-scale population studies. A summary of these biomarkers, including oncogenic, nc-RNAs, is presented in Table 1.

Table 1: Molecular biomarkers for PCa.

Types Biomarkers Function Sample types Detection methods References Genetic Alteration TMPRSS2-ERG Diagnosis, Prognosis Urine, Tissue PCR, NGS [21] PTEN Diagnosis, Prognosis Blood, Tissue IHC, FISH, NGS [34] MYC Prognosis Blood, Tissue FISH, NGS [42] AR Diagnosis, Prognosis Blood, Tissue IHC, NGS, qRT-PCR [49,55] TP53 Prognosis Tissue IHC, NGS [148] DNA Methylation GSTP1 Diagnosis Blood, Tissue MSP, qRT-PCR [65] ACTL6B Prognosis Blood MSP [69] TCERG1 Prognosis Blood, Tissue MSP [69] Histone Modification KMT1B Prognosis Tissue Western Blot, Mass Spectrometry [79] SMYD3 Prognosis Tissue Western Blot, Mass Spectrometry [81] SETDB1 Prognosis Tissue IHC, Western Blot [82] PRMT5 Prognosis Tissue IHC, Western Blot [83] p300/CBP Prognosis Tissue Chromatin Immunoprecipitation [84] METTL3 Prognosis Tissue IHC, Western Blot [91] METTL14 Prognosis Tissue IHC, Western Blot [92] NSUN2 Prognosis Tissue IHC, Western Blot [93] miRNA miR-21 Diagnosis, Prognosis Blood, Urine qRT-PCR, Microarray [101] miR-34a Prognosis Blood qRT-PCR, Microarray [102] miR-107 Diagnosis, Prognosis Blood, Urine qRT-PCR, Microarray [103] miR-199a-3p Prognosis Blood qRT-PCR, Microarray [104] lncRNA PCA3 Diagnosis Urine qRT-PCR, Urine Tests [25] SNHG1 Diagnosis, Prognosis Blood, Urine qRT-PCR, NGS [119] PCAT1 Diagnosis, Prognosis Blood, Urine qRT-PCR, NGS [120] MALAT1 Diagnosis, Prognosis Blood, Urine qRT-PCR, NGS [122] circRNA circ_0044516 Prognosis Blood qRT-PCR, NGS [126] hsa_circ_0001275 Diagnosis, Prognosis Blood qRT-PCR, NGS [127] MOLECULAR DIAGNOSTIC TECHNIQUES Liquid biopsy

The liquid biopsy has become a compelling and promising approach in molecular diagnostics. It serves as a minimally invasive or non-invasive technique for analyzing a range of biomarkers in blood or other body fluids for diagnosing cancer, assessing prognosis, and monitoring treatment responses. These biomarkers include CTCs, extracellular vehicles (EVs), ctDNA, and ctRNA.[129,130] Given that advanced tumor tissues are rarely obtained and may not reflect the current biological status of tumor staging, liquid biopsy is becoming an attractive resource for biomarker evaluation.

Since CTCs from primary tumors can be detected in the blood or urine of PCa patients, research on CTCs in PCa is the most advanced. CTCs have been proven to be valuable biomarkers, especially in advanced diseases such as mCRPC.[131-133] de Bono et al.[134] demonstrated that favorable CTCs counts (≤5 cells/7.5 mL of blood) could predict significantly better PFS and OS following treatment. Crucially, CTCs isolated from PCa patients can display molecular features such as increased AR copy numbers, AR mutations, PTEN loss, and TMPRSS2-ETS gene fusions, which are crucial for tumor characterization.[135] The focus of research on PCa CTCs is shifting from quantitative a